Oxazolidinones in the Clinical Management of Staphylococcal Infection-Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS).

IF 4.1 2区医学 Q1 INFECTIOUS DISEASES

Journal of Antimicrobial Chemotherapy Pub Date : 2026-10-06 DOI:10.1093/jac/dkag323

Liana Macpherson, Anne-Grete Martson, Jose L Del Pozo, Cindy Zheng, Anna L Goodman

{"title":"Oxazolidinones in the Clinical Management of Staphylococcal Infection-Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS).","authors":"Liana Macpherson, Anne-Grete Martson, Jose L Del Pozo, Cindy Zheng, Anna L Goodman","doi":"10.1093/jac/dkag323","DOIUrl":null,"url":null,"abstract":"<p><p>There is limited information in the existing literature regarding the choice of oxazolidinone in clinical practice to treat infections caused by staphylococcal species. As members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS) we have collaborated and written this narrative review aimed at clinicians considering these agents in practice. The review focuses on two medications, linezolid and tedizolid, with a comprehensive description of pharmacology aspects, adverse effects, drug interactions and contraindications, and we investigate the potential for treatment optimization. We anticipate that this article will provide support for those considering utilization of linezolid and tedizolid in clinical practice to treat staphylococcal species.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655609/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antimicrobial Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jac/dkag323","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

There is limited information in the existing literature regarding the choice of oxazolidinone in clinical practice to treat infections caused by staphylococcal species. As members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS) we have collaborated and written this narrative review aimed at clinicians considering these agents in practice. The review focuses on two medications, linezolid and tedizolid, with a comprehensive description of pharmacology aspects, adverse effects, drug interactions and contraindications, and we investigate the potential for treatment optimization. We anticipate that this article will provide support for those considering utilization of linezolid and tedizolid in clinical practice to treat staphylococcal species.

查看原文本刊更多论文

恶唑烷类药物在葡萄球菌感染临床治疗中的应用——利奈唑胺还是泰地唑胺？代表欧洲临床微生物学和传染病学会（ESCMID）葡萄球菌和葡萄球菌疾病（ESGS）研究组进行的综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Antimicrobial Chemotherapy 医学-传染病学

CiteScore

9.20

自引率

5.80%

发文量

423

审稿时长

2-4 weeks

期刊介绍： The Journal publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, and articles in veterinary medicine likely to have an impact on global health.